Applications include the use of sVEGFR3 as a BACE2 marker in conditions characterized by altered sVEGFR3 levels, e.g., preeclampsia, hypertension in systemic sclerosis, or treatment-induced changes in sVEGFR3 in VEGFR3-dependent diseases, such as sunitinib-treated cancers (26, 48, 49). Here, BACE2 is linked to cancer.